Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auto-HCT Followed by Maintenance Rituximab vs Maintenance Rituximab Alone in MRD-Negative Mantle Cell Lymphoma
NCT03267433Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Nov 2017
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of rituximab in mantle cell lymphoma (MCL), sponsored by ECOG-ACRIN Cancer Research Group. Started Nov 2017; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03267433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267433.